• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

    4.105 -0.055 (-1.32%)
    Streaming Delayed Price Updated: 11:45 AM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 127,930
    Open 4.110
    Bid (Size) 4.100 (700)
    Ask (Size) 4.110 (400)
    Prev. Close 4.160
    Today's Range 4.045 - 4.160
    52wk Range 1.140 - 7.200
    Shares Outstanding 58,576,350
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
    Via Chartmill

    Performance

    YTD
    -12.1%
    -12.1%
    1 Month
    -17.1%
    -17.1%
    3 Month
    -27.0%
    -27.0%
    6 Month
    -9.2%
    -9.2%
    1 Year
    -19.7%
    -19.7%

    More News

    Read More
    News headline image
    Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗
    Via Stocktwits
    News headline image
    Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗
    Via Stocktwits
    News headline image
    Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
    Via Benzinga
    News headline image
    4 Biotech Stocks Seeing Explosive Momentum Gains ↗
    Via Benzinga
    Topics ETFs Stocks
    News headline image
    Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
    Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
    What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
    The current price of Aldeyra Therapeutics, Inc. - Common Stock is 4.105
    When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 01/08/26 11:45 AM ET
    What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
    The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 240.46M
    How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
    Aldeyra Therapeutics, Inc. - Common Stock has 240M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.